Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod effects on myelin dynamics and neurodegeneration in relapsing-remitting multiple sclerosis
2021-003577-63Phase 4Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozanimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by IRCCS Ospedale San Raffaele. Started Sep 2022; status: active.
02
Drugs
ozanimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2021-003577-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003577-63.